ULK1 as a novel therapeutic target in neurodegeneration

Björn Vahsen; Paul Lingor

doi:10.4103/1673-5374.300442

ULK1 as a novel therapeutic target in neurodegeneration

Björn Vahsen
, Paul Lingor

Department of Neurology

University of Oxford Medical Sciences Division
University Medical Center

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	1212-1213
Number of pages	2
Journal	Neural Regeneration Research
Volume	16
Issue number	6
DOIs	https://doi.org/10.4103/1673-5374.300442
State	Published - Jun 2021

Access to Document

10.4103/1673-5374.300442

Cite this

@article{0b52eb16fe924c8fbb7d3d611e42277c,

title = "ULK1 as a novel therapeutic target in neurodegeneration",

author = "Bj{\"o}rn Vahsen and Paul Lingor",

note = "Funding Information: Finally ? we confirmed some of the key findings of disease.for a therapeutic modulation of ULK1 in human U?? 堀᠀䔃爁甁ḁᨁ崁?ted U??  inhibition using the small ? al., 2020). Indeed, treatment of retinal ganglionmolecule ULK1inhibitorSBI-0206965(Vahsenet BFV?was?supported?by?a?scholarship?from?the? DepartmentofNeurology ,UniversityMedic al? cells with SBI-0206965 attenuated AAD for up to Center?G{\"o}ttingen.?PL?received?funding?from?the? 6 hours after optic nerve crush lesion in a dose-Cluster?of?Excellence?and?DFG?Research?Center? dependent manner. Corresponding to our results Nanoscale?Microscopy?and?Molecular?Physiology?",

year = "2021",

month = jun,

doi = "10.4103/1673-5374.300442",

language = "English",

volume = "16",

pages = "1212--1213",

journal = "Neural Regeneration Research",

issn = "1673-5374",

publisher = "Wolters Kluwer Medknow Publications",

number = "6",

}

TY - JOUR

T1 - ULK1 as a novel therapeutic target in neurodegeneration

AU - Vahsen, Björn

AU - Lingor, Paul

N1 - Funding Information: Finally ? we confirmed some of the key findings of disease.for a therapeutic modulation of ULK1 in human U?? 堀᠀䔃爁甁ḁᨁ崁?ted U??  inhibition using the small ? al., 2020). Indeed, treatment of retinal ganglionmolecule ULK1inhibitorSBI-0206965(Vahsenet BFV?was?supported?by?a?scholarship?from?the? DepartmentofNeurology ,UniversityMedic al? cells with SBI-0206965 attenuated AAD for up to Center?Göttingen.?PL?received?funding?from?the? 6 hours after optic nerve crush lesion in a dose-Cluster?of?Excellence?and?DFG?Research?Center? dependent manner. Corresponding to our results Nanoscale?Microscopy?and?Molecular?Physiology?

PY - 2021/6

Y1 - 2021/6

UR - https://www.scopus.com/pages/publications/85097407729

U2 - 10.4103/1673-5374.300442

DO - 10.4103/1673-5374.300442

M3 - Review article

AN - SCOPUS:85097407729

SN - 1673-5374

VL - 16

SP - 1212

EP - 1213

JO - Neural Regeneration Research

JF - Neural Regeneration Research

IS - 6

ER -

ULK1 as a novel therapeutic target in neurodegeneration

Access to Document

Other files and links

Cite this